Sponsor study identifier
interventional
100
1 country
1
Study Start
March 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Oxidative stress occurs as a result of increased activity of free radical-producing enzymes, decreased activity of free radical-removing enzymes, and insufficient levels of antioxidants. The most sensitive molecules to oxidation are lipids. Loss of cell membrane elasticity, increased cell fragility, and a shortened cellular life span results from oxidation of cell membrane lipids.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 6, 2013
Actual (reported)January 9, 2013
Actual (reported)March 2013
Date type not reportedThis date has not been verified as actual or estimated.
September 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
September 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
oxidant status in ITP
oxidant and antioxidant systems initially in patients with acute and chronic immune thrombocytopenia (ITP)
6 month
antioxidant therapy
6 months
interventional arm 1 and will receive antioxidant therapy (Antox tablets ( 1 tablet contains : Vit. A 2000 IU, Vit C 90 mg, Vit E 15 mg and selenium yeast 55 ug ) with the therapy selected for ITP tailored according to patient's presentation.For Antox tablets it will be given daily for 6 months.
drug therapy for ITP according to ASH, 2011 guidelines.
effect of antioxidant on disease outcome
drugs will be selected according to ASH,2011 guidelines
hematology clinic ,pediatrics hospital, Ain Shams University hospital Cairo, Egypt
Cairo, Egypt
Mohsen S Elalfy, professor
Ain Shams University
First Submitted
January 6, 2013
First Posted
January 9, 2013
Study Start
March 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2013
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
January 9, 2013
Record last verified: 2013-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: